Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
01 October 2013Website:
http://www.fatetherapeutics.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 4 min agoDividend
Analysts recommendations
Institutional Ownership
FATE Latest News
PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Fate Therapeutics, Inc. (NASDAQ: FATE) ("Fate") on behalf of the company's long-term investors. Recently an amended securities fraud complaint was filed against Fate on behalf of certain investors who purchased shares of the company's stock between August 5, 2020 and January 5, 2023.
Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.
Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.
Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript
Fate Therapeutics (FATE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.58 per share a year ago.
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Monday, February 26, 2024 at 5:00 PM ET to report its fourth quarter and full year 2023 financial results and provide a corporate update.
Fate Therapeutics (FATE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
When billionaire investors step into a particular smaller-cap under-the-radar name, investors take notice. That appears to be the case with Fate Therapeutics (NASDAQ: FATE ) today.
Fate Therapeutics (FATE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 1(current)
What type of business is Fate Therapeutics?
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing programmable cellular immunotherapies for the treatment of cancer and immune disorders. The corporation was registered in the state of Delaware in 2007, with headquarters in San Diego, California. The company is developing programmable cellular immunotherapeutic agents for the treatment of oncological diseases and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapy based on engineered induced pluripotent cells, and immune regulation programs, including immunotherapy with hematopoietic cells to protect the immune system of patients who have undergone hematopoietic cell transplantation, and to suppress autoimmune reactions.
What sector is Fate Therapeutics in?
Fate Therapeutics is in the Healthcare sector
What industry is Fate Therapeutics in?
Fate Therapeutics is in the Biotechnology industry
What country is Fate Therapeutics from?
Fate Therapeutics is headquartered in United States
When did Fate Therapeutics go public?
Fate Therapeutics initial public offering (IPO) was on 01 October 2013
What is Fate Therapeutics website?
https://www.fatetherapeutics.com
Is Fate Therapeutics in the S&P 500?
No, Fate Therapeutics is not included in the S&P 500 index
Is Fate Therapeutics in the NASDAQ 100?
No, Fate Therapeutics is not included in the NASDAQ 100 index
Is Fate Therapeutics in the Dow Jones?
No, Fate Therapeutics is not included in the Dow Jones index
When does Fate Therapeutics report earnings?
The next expected earnings date for Fate Therapeutics is 08 August 2024